Alps Advisors Inc. bought a new stake in MoonLake Immunotherapeutics (NASDAQ:MLTX – Get Rating) in the second quarter, according to the company in its most recent filing with the Securities and Exchange Commission (SEC). The fund bought 31,260 shares of the company’s stock, valued at approximately $164,000. Alps Advisors Inc. owned about 0.21% of MoonLake Immunotherapeutics at the end of the most recent quarter.
A number of other institutional investors also recently modified their holdings of MLTX. Cowen AND Company LLC bought a new position in MoonLake Immunotherapeutics in the 2nd quarter worth approximately $85,000. Meridian Wealth Management LLC bought a new position in MoonLake Immunotherapeutics in the 2nd quarter worth approximately $142,000. Finally, TD Asset Management Inc. bought a new position in MoonLake Immunotherapeutics in the 2nd quarter worth approximately $152,000.
Wall Street Analysts Forecast Growth
Several research firms recently weighed in on MLTX. Jefferies Financial Group began coverage on shares of MoonLake Immunotherapeutics in a research report on Friday, November 11th. They issued a “buy” rating and a $16.00 price objective for the company. SVB Leerink began coverage on shares of MoonLake Immunotherapeutics in a research report on Thursday, August 25th. They issued an “outperform” rating and a $17.00 price objective for the company. Five equities research analysts have rated the stock with a buy rating, According to data from MarketBeat.com, the stock presently has a consensus rating of “Buy” and an average target price of $20.33.
MoonLake Immunotherapeutics Trading Up 1.6 %
MoonLake Immunotherapeutics Company Profile
MoonLake Immunotherapeutics, a clinical-stage biopharmaceutical company, engages in developing therapies. It is developing Sonelokimab, a novel investigational Nanobody therapy for the treatment of inflammation. The company is involved in conducting Phase II trials for hidradenitis suppurativa, psoriatic arthritis, ankylosing spondylitis, or radiographic axial spondyloarthritis.
- Get a free copy of the StockNews.com research report on MoonLake Immunotherapeutics (MLTX)
- Three CBD Stocks to Dominate a Budding Industry
- Microsoft Shares: Is it Time to Back Up the Truck?
- Institutional Support for Analog Devices Remains High
- Salesforce Cuts Labor, Shows Strong Earnings Despite Challenges
- Is the 60/40 Portfolio Mix Still in Vogue?
Receive News & Ratings for MoonLake Immunotherapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for MoonLake Immunotherapeutics and related companies with MarketBeat.com's FREE daily email newsletter.